Cholesterol is known to slow the activity of tuberculosis, and the new research suggests a modified version of the compound could stop the bacteria responsible for the deadly infections from growing altogether.
“The results presented here thus implicate a distinct and more robust mechanism of growth inhibition,” study authors concluded. “They define a new paradigm for the development of agents that can, at least in culture, block the growth of Mycobacterium tuberculosis. Further exploration of this paradigm is a promising route for the development of therapeutically useful inhibitors.”
The findings are published in the Journal of Biological Chemistry.
More articles on infection control:
CDC worker possibly infected with laboratory-acquired Salmonella
5 things to know about Zika misperceptions in the US
Lab-confirmed flu cases begin to fall, but overall rates remain elevated
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
